Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Show other versions (1)

OBJECTIVE: The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody secukinumab was safe and effective for the treatment of active Crohn's disease. DESIGN: In a double-blind, randomised, placebo-controlled proof-of-concept study, 59 patients with moderate to severe Crohn�...

Full description

Bibliographic Details
Main Authors: Hueber, W, Sands, B, Lewitzky, S, Vandemeulebroecke, M, Reinisch, W, Higgins, P, Wehkamp, J, Feagan, BG, Yao, MD, Karczewski, M, Karczewski, J, Pezous, N, Bek, S, Bruin, G, Mellgard, B, Berger, C, Londei, M, Bertolino, A, Tougas, G, Travis, S
Format: Journal article
Language:English
Published: 2012

Similar Items